Drugs / Rifafour e-275
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02953847 | Nov 2016 → Feb 2017 | tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05382312 | Jul 2022 → May 2025 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00401271 | Nov 2006 → Mar 2007 | pulmonary tuberculosis | Otsuka Frankfurt Research Institute GmbH | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03557281 Comparator | Mar 2019 → Dec 2021 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT05896930 Comparator | Nov 2017 → Jan 2021 | pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT02349841 Comparator | Sep → Dec 2014 | pulmonary tuberculosis | TASK Applied Science | Completed | No outcome recorded |
| Phase 2 | NCT00944021 Comparator | Aug 2009 → Jan 2010 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RIFAFOUR e-275 | “RIFAFOUR e-275 is a registered trademark of Sanofi-Aventis.” NCT03557281 ↗ |
| Route | Oral | “Rifafour e-275 will be administered orally once daily for 14 days” NCT02349841 ↗ |